Polatuzumab,Rituximab,Doxorubicin,Prednisone
roche,abbvie,biogen
['lymsm', 'dlbcl']
a thoughtful, independent cost-effectiveness analysis that will inform clinicians (and htas!) deciding about pola-r-chp in dlbcl &amp; should be commended. hopefully time confirms positive findings #lymsm #asco22 
haematology registrar | evidence-based medicine | MPH @Harvard | health policy @PORTAL_research | physiology | musician | writer | @_futurethinkers cofounder